Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety and Efficacy Study of Chimeric Switch Receptor Modified T Cells in Patients With Recurrent or Metastatic Malignant Tumors

NCT02930967 is registered in ClinicalTrials.gov with China Meitan General Hospital as lead sponsor.

NCT NCT02930967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02930967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety and Efficacy Study of Chimeric Switch Receptor Modified T Cells in Patients With Recurrent or Metastatic Malignant Tumors
Lead sponsor
China Meitan General Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
August 31, 2016
Completion date
August 31, 2019
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pd-l1+ malignant tumors, recurrent pd-l1+ malignant tumors